RARE
UltragenyxNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.30B
P/E Ratio
—
EPS
$-6.10
Beta
0.39
52W High
$42.37
52W Low
$18.29
50-Day MA
$23.33
200-Day MA
$27.54
Dividend Yield
—
Profit Margin
-90.90%
Forward P/E
—
PEG Ratio
-0.24
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Fundamentals
| Revenue (TTM) | $670.00M |
| Gross Profit (TTM) | $-188.00M |
| EBITDA | $-497.00M |
| Operating Margin | -102.20% |
| Return on Equity | -608.00% |
| Return on Assets | -25.50% |
| Revenue/Share (TTM) | $6.72 |
| Book Value | $-0.83 |
| Price-to-Book | 247.70 |
| Price-to-Sales (TTM) | 3.44 |
| EV/Revenue | 2.479 |
| EV/EBITDA | -6.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -2.20% |
| Shares Outstanding | $98.49M |
| Float | $94.59M |
| % Insiders | 3.46% |
| % Institutions | 104.07% |
Historical Volatility
HV 10-Day
52.22%
HV 20-Day
42.33%
HV 30-Day
40.66%
HV 60-Day
49.78%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($52.05 target)
5
Strong Buy13
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026